| abstract |
The invention relates to the use of immunomodulators in order to help with standard treatment against infectious diseases caused by facultative intracellular organisms. The invention is based on an analysis of the immune response established during said type of infections and, in particular, that produced by tuberculosis. Taking account of the aforementioned analysis, the invention consists in using a treatment kit associating a soluble betaglycan-type immunomodulator with an anti-inflammatory agent of the prostaglandin E-blocker type, which, when used together, modulate the immune response, thereby enabling the treatment time with respective antibiotics to be shortened. |